1. Home
  2. ETON vs BOLD Comparison

ETON vs BOLD Comparison

Compare ETON & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$23.54

Market Cap

689.8M

Sector

Health Care

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.55

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETON
BOLD
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
689.8M
36.5M
IPO Year
2018
2024

Fundamental Metrics

Financial Performance
Metric
ETON
BOLD
Price
$23.54
$1.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$39.33
$4.00
AVG Volume (30 Days)
424.7K
397.0K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
$79,950,000.00
N/A
Revenue This Year
$40.90
N/A
Revenue Next Year
$47.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
104.94
N/A
52 Week Low
$13.09
$0.96
52 Week High
$27.29
$1.78

Technical Indicators

Market Signals
Indicator
ETON
BOLD
Relative Strength Index (RSI) 49.27 67.19
Support Level $16.23 $1.08
Resistance Level $27.29 $1.55
Average True Range (ATR) 1.15 0.09
MACD -0.53 0.04
Stochastic Oscillator 5.18 77.87

Price Performance

Historical Comparison
ETON
BOLD

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: